Sandoz will stand alone in more ways than one by the end of this year, CEO Richard Saynor has indicated to Generics Bulletin in the first part of an exclusive three-part interview, with the company spinning off from parent company Novartis while also occupying a unique position among its peer group as the only one of the big three off-patent companies to have a pure focus on generics and biosimilars.
Last year Novartis announced that, following a strategic review of the Sandoz generics and biosimilars unit, it would be spun off into a publicly traded, standalone company in the second half of 2023